Skip to Main Content

Merck pulled the plug on a closely watched trial in Alzheimer’s disease after finding out its in-development drug had no effect on patients with mild forms of the disorder.

The drug, verubecestat, showed “virtually no chance” of meeting its goal in a 2,200-patient study, Merck said. The trial was meant to read out later this year, but Merck, on the advice of its independent data monitors, pulled the plug early.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED